Molecular targets of cisplatin in HeLa cells explored through competitive activity-based protein profiling strategy

J Inorg Biochem. 2024 Mar 6;254:112518. doi: 10.1016/j.jinorgbio.2024.112518. Online ahead of print.ABSTRACTCisplatin is widely used as anticancer drugs, and DNA is considered as the main target. Considering its high affinity towards cysteines and the important role of cystine containing proteins, we applied a competitive activity-based protein profiling strategy to identify protein cysteines that bind with cisplatin in HeLa cells. Living cells were treated with cisplatin at cytotoxic concentrations, then the protein was extracted. After labeling with desthiobiotin iodoacetamide (DBIA) probe, protein was precipitated, digested and isotopically labeled, subsequently the peptides were combined, and the biotinylated cysteine-containing peptides were enriched and quantified by LC-MS/MS. A total of 3571 peptides which originated from 1871 proteins were identified using the DBIA probe. Among them, 46 proteins were screened as targets, including proteins that have been identified as binding proteins by previous study. A novel cisplatin target, calpain-1 (CAPN1), was identified and validated as binding with cisplatin in vitro.PMID:38460483 | DOI:10.1016/j.jinorgbio.2024.112518

Source: Journal of Inorganic Biochemistry - March 9, 2024 Category: Biochemistry Authors: Yi Chen Chenxi Wang Meiling Qi Yinyu Wei Hongliang Jiang Zhifeng Du Source Type: research